Arbutus Biopharma Corp (ABUS)

05:26 AM

Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed - Quiver Quantitative

05:26 AM

02:33 AM

Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus

02:33 AM

11:30 AM

Arbutus Biopharma Corporation Files Form 8-K with SEC – Company Details, Address, and NASDAQ Listing Information 24252675 - Minichart

11:30 AM

11:11 AM

ABUS Receives Fast Track Designation from FDA for Imdusiran - GuruFocus

11:11 AM

07:31 AM

[8-K] Arbutus Biopharma Corp Reports Material Event - Stock Titan

07:31 AM

07:30 AM

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - GlobeNewswire

07:30 AM

Apr 14, 2026

Arbutus Biopharma (ABUS) 2026 proxy adds 16.3M-share incentive plan vote - Stock Titan

Apr 14, 2026

Apr 13, 2026

Whitefort outlines 8.1% Arbutus Biopharma (ABUS) stake in amended 13D - Stock Titan

Apr 13, 2026

Apr 10, 2026

ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill

Apr 10, 2026

Apr 09, 2026

ABUS Should I Buy - Intellectia AI

Apr 09, 2026

Apr 08, 2026

Arbutus reports results, announces $2.25B Moderna settlement - MSN

Apr 08, 2026

Apr 07, 2026

ABUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 07, 2026

Apr 05, 2026

Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure - Markets Mojo

Apr 05, 2026

Apr 05, 2026

Arbutus Reports Results, Announces $2.25B Moderna Settlement - MyChesCo

Apr 05, 2026

Apr 03, 2026

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com

Apr 03, 2026

Apr 02, 2026

ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill

Apr 02, 2026

Mar 29, 2026

ABUS PE Ratio & Valuation, Is ABUS Overvalued - Intellectia AI

Mar 29, 2026

Mar 25, 2026

Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2026

Mar 24, 2026

Arbutus: Q4 Earnings Snapshot - theheraldreview.com

Mar 24, 2026

Mar 24, 2026

Arbutus Biopharma Corporation (ABUS) Form 8-K Filing Details, Key Financials, and Company Information - Minichart

Mar 24, 2026

Mar 23, 2026

Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives - simplywall.st

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma 2025 Financials: Reduced Annual Loss, Revenue GrowthNews and Statistics - IndexBox

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma earnings missed by $0.14, revenue topped estimates - investing.com

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma 2025 Annual Report: Clinical Pipeline, Patent Litigation, and Strategic Outlook - Minichart

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma (ABUS) Misses EPS Estimates but Exceeds Revenue Expectations - GuruFocus

Mar 23, 2026

Mar 23, 2026

Arbutus: Fourth Quarter Financial Results Overview - Bitget

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results - MarketBeat

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan

Mar 23, 2026

Mar 23, 2026

Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan

Mar 23, 2026

Mar 23, 2026

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 23, 2026

Mar 22, 2026

Market Moves: Is Arbutus Biopharma Corporation attractive at current valuation2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn

Mar 22, 2026

Mar 19, 2026

Arbutus Biopharma (ABUS) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Mar 19, 2026

Mar 18, 2026

Moderna to pay about $1 billion to settle Arbutus litigation - MSN

Mar 18, 2026

Mar 16, 2026

Foursixthree Capital LP Has $8.99 Million Stake in Arbutus Biopharma Corporation $ABUS - MarketBeat

Mar 16, 2026

Mar 12, 2026

Arbutus Biopharma (NASDAQ:ABUS) Shares Down 8.4%Time to Sell? - MarketBeat

Mar 12, 2026

Mar 12, 2026

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat

Mar 12, 2026

Mar 11, 2026

Moderna Settles Patent Litigation with Arbutus et al. - JD Supra

Mar 11, 2026

Mar 06, 2026

Arbutus Biopharma Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Mar 06, 2026

Mar 05, 2026

9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com

Mar 05, 2026

Mar 05, 2026

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com

Mar 05, 2026

Mar 05, 2026

Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Claims Journal

Mar 05, 2026

Mar 04, 2026

ABUS SEC FilingsArbutus Biopharm 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 04, 2026

Mar 04, 2026

Here's Arbutus Biopharma's share of $950M Moderna settlement - The Business Journals

Mar 04, 2026

Mar 04, 2026

Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Mar 04, 2026

Mar 04, 2026

Arbutus Biopharma (ABUS) Reaches Settlement with Moderna Over Pa - GuruFocus

Mar 04, 2026

Mar 04, 2026

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal By Investing.com - Investing.com Canada

Mar 04, 2026

Mar 04, 2026

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Finviz

Mar 04, 2026

Mar 04, 2026

ABUS: Key Developments and Market Impact - GuruFocus

Mar 04, 2026

Mar 04, 2026

Moderna's $950 Million Settlement Clears Legal Overhang, Stock SoarsModerna (NASDAQ:MRNA) - Benzinga

Mar 04, 2026

Mar 04, 2026

Moderna to pay about US$1 bil to settle Arbutus litigation - The Edge Malaysia

Mar 04, 2026

Mar 04, 2026

Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter

Mar 04, 2026